OvaScience
Applying innovative science to enhance egg quality and increase IVF success through proprietary technology that leverages a woman’s own cellular energy
Applying innovative science to enhance egg quality and increase IVF success through proprietary technology that leverages a woman’s own cellular energy
OvaScience is a biotechnology startup that aims to revolutionize the field of in vitro fertilization (IVF) by enhancing egg quality through innovative science. The company's proprietary technology, licensed from Harvard Medical School and Massachusetts General Hospital, harnesses a woman's cellular energy to improve the quality of eggs. Co-founded by Richard Aldrich, Michelle Dipp, M.D., Ph.D., and Christoph Westphal, M.D., Ph.D. of Longwood Founders Fund, along with fertility expert Jonathan Tilly, Ph.D. of Massachusetts General Hospital, and aging expert David Sinclair, Ph.D. of Harvard Medical School, OvaScience is supported by leading life science investors Longwood Founders Fund and Bessemer Venture Partners.
Founded in 2011, OvaScience operates in the Biotechnology and Health Care industries. The company received a significant $53.80M post-IPO equity investment on 01 June 2016. OvaScience boasts a world-class team of top reproductive endocrinologists, embryologists, scientists, and advisors dedicated to bringing this groundbreaking technology to patients.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $53.80M | - | 01 Jun 2016 | |
| Post-IPO Equity | $132.00M | - | 12 Jan 2015 | |
| Post-IPO Equity | $50.00M | - | 04 Mar 2014 | |
| Post-IPO Equity | $35.00M | - | 28 Mar 2013 | |
| Series C | $4.00M | - | 07 Aug 2012 |
No recent news or press coverage available for OvaScience.
We care about your data, and we'd love to use cookies make your experience better.